

Evaluate Custom Services

Evaluate Custom Services

Customised solutions to help you access, analyse and manage the information you need to support effective decision-making.



A key challenge facing life sciences companies is accessing the right data and insight, at the right time, in order to make informed decisions. Evaluate offers custom services that couple our deep industry expertise with our life science market intelligence, evaluation tools and forecasts. Custom solutions are designed on a project by project basis, to maximise the value of our data and drive actionable insights. Our services team works with you in close collaboration from the start to understand project requirements and design the right solution with you.

Selected challenges we have helped our clients with:

Access

"I need a highly specific customised dataset to feed into an upcoming management report."

"I need EvaluatePharma content with additional tags and data points for an ongoing screening and evaluation project."

Analyse

"I want to understand how the market and competitive landscape is evolving quarter by quarter."

"I want to benchmark competitor activity and get an objective third party view to build into my business planning process."

Manage

"I need a regular data feed to incorporate into an internal data visualisation tool for our BD&L group."

"I need a customised view of the EvaluatePharma content according to my definitions and hierarchies to match internal reporting systems."

Custom Services Leadership Team

Paul Verdin, Head of Services

Paul manages the overall services business. Following a PhD in neuropharmacology, Paul has pursued a career providing data-driven support to the biopharma and related industries, collaborating with clients to address key business challenges across the R&D and commercial lifecycle.



Jon Moser, Services Delivery Lead

Jon works with Paul to manage end to end delivery of client projects. Jon has deep industry and Evaluate data expertise, having developed and shaped Evaluate's core subscription content over the last decade. Jon's background is in Biochemistry, Accountancy, and biopharma analytics.





Access

Custom datasets based fully or partially on existing Evaluate content, aggregated, manipulated, and extended according to your needs.

Solutions include:

- Customised Evaluate data extracts
- Extensions of existing Evaluate datasets
- Archive data

Rank	Company	Pipeline	Clinical Status	Therapeutic Indication	Phase	Market	Value
1	OncoGenex	OncoGenex	Phase II	Other oncology	Phase II	Marketed	8,248
2	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	7,700
3	Amgen	Amgen	Phase III	Other oncology	Phase III	Marketed	6,730
4	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	6,512
5	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	6,050
6	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,999
7	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,950
8	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,899
9	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,848
10	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,797
11	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,746
12	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,695
13	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,644
14	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,593
15	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,542
16	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,491
17	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,440
18	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,389
19	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,338
20	Novartis	Novartis	Phase III	Other oncology	Phase III	Marketed	5,287


Sample data extract: most valuable Oncology assets by net present value and evolution in valuation during 2015

Analyse

Analytical solutions combining Evaluate content, targeted external research, industry expertise, and our structured and tailored methodologies.

Solutions include:

- Regular management information reports
- Benchmarking analysis
- Pipeline tracking
- Trend analysis (e.g. forecast vs actual)




Manage

Data management services to help you get the right information, at the right time, and in the right format.

Solutions include:

- Custom data feeds and technical solutions to integrate Evaluate content into your internal systems
- Customised definitions and subscription views
- Curation and news monitoring services





Established in 1996, Evaluate Ltd is the trusted leader in high quality life science sector analysis and consensus forecasts to 2020. Evaluate's team of expert analysts transform life science information into insights so companies can perform well.



[www.evaluate.com/
customservices](http://www.evaluate.com/customservices)

EvaluatePharma[®] delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

 [@EvaluatePharma](https://twitter.com/EvaluatePharma)

EvaluateMedTech[®] sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

 [@EvaluateMedTech](https://twitter.com/EvaluateMedTech)

EvaluateClinical Trials[®] delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

 [@EPClinicalTrial](https://twitter.com/EPClinicalTrial)

EP Vantage an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

 [@EPVantage](https://twitter.com/EPVantage)

Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

www.evaluate.com

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801

Evaluate North America

EvaluatePharma USA Inc.
15 Broad Street, Suite 401
Boston, MA 02109, USA
T +1 617 573 9450
F +1 617 573 9542

Evaluate Japan

Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052, Japan
T +81 (0)80 1164 4754